Scinai Immunotherapeutics Ltd.
SCNI
$1.13
-$0.14-11.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 386.50K | 386.50K | 206.00K | 284.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 386.50K | 386.50K | 206.00K | 284.00K | -- |
| Cost of Revenue | 1.02M | 1.02M | 373.00K | 448.00K | -- |
| Gross Profit | -635.00K | -635.00K | -167.00K | -164.00K | -- |
| SG&A Expenses | 628.00K | 628.00K | 759.00K | 519.00K | 968.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 124.00K | -- |
| Total Operating Expenses | 2.27M | 2.27M | 2.47M | 2.31M | 2.10M |
| Operating Income | -1.88M | -1.88M | -2.26M | -2.03M | -2.10M |
| Income Before Tax | -2.07M | -2.07M | -2.23M | -2.32M | -3.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.07M | -2.07M | -2.23M | -2.32M | -3.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.07M | -2.07M | -2.23M | -2.32M | -3.11M |
| EBIT | -1.88M | -1.88M | -2.26M | -2.03M | -2.10M |
| EBITDA | -1.53M | -1.53M | -1.76M | -1.53M | -1.96M |
| EPS Basic | -5.20K | -5.20K | -22.74K | -14.57K | -26.49K |
| Normalized Basic EPS | -0.81 | -0.81 | -8.59 | -2.28 | -- |
| EPS Diluted | -5.20K | -5.20K | -22.74K | -14.57K | -26.49K |
| Normalized Diluted EPS | -0.81 | -0.81 | -8.59 | -2.28 | -- |
| Average Basic Shares Outstanding | 1.59M | 1.59M | 1.24M | 637.60K | 469.20K |
| Average Diluted Shares Outstanding | 300.00 | 300.00 | 300.00 | 100.00 | 100.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |